Значения термина active ra на английском

Patients with severe active RA underwent repeated leukapheresis procedures that removed all circulating monocytes.

Methods: Patients with active RA initiating their first treatment course of TNF-blocking therapy were enrolled.

Results: Endothelial cells from patients with active RA had high angiogenic growth capacity compared with controls.

Conclusion: Apremilast efficacy was not demonstrated in patients who had active RA despite stable MTX therapy.

We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in patients with active RA.

We tested the hypothesis that these associated with disease severity in a clinical trial cohort of patients with early, active RA.

In this study, we investigated the effect of TGP on hepatic dysfunction caused by MTX and LEF in patients with active RA.

PsA patients had cytokine levels similar to healthy controls, while RA patients in remission had similar levels to those of active RA patients.

Our preliminary study demonstrates the hepatoprotective and additive role of TGP in combination with MTX and LEF in the treatment of active RA.

Results: A total of 294 patients were included: 66 RA in remission, 146 active RA, and 82 NIA.

Results: 30 RA and 47 PsA patients in remission, 22 active RA patients and 20 healthy controls were included.

Conclusions: Over 24 weeks, filgotinib as monotherapy was efficacious in treating the signs and symptoms of active RA, with a rapid onset of action.

Methods: A total of 105 patients with persistently active RA and poor responses to traditional medication were randomly divided into MSCT and control groups.

Early intervention with infliximab in patients with active RA despite MTX therapy may provide long term benefits by preventing radiographic progression and preserving joint integrity.

The aim of this study was to determine the effect of B cell depletion with rituximab on serum visfatin levels in patients with active RA.

This was a multicenter, randomized, placebo-controlled trial that evaluated the safety and tolerability of rhIL-11 in 91 patients with active RA.